Atherochek-5 Tab

Side Effects of Atherochek-5 Tab

Headache, flatulence, constipation, dyspepsia, nausea, diarrhoea, vomiting, anorexia. Pain in extremity, musculoskeletal and pharyngolaryngeal; myopathy, muscle spasms, myalgia, arthralgia, nasopharyngitis, insomnia, UTI. Increased serum aminotransferase, glycosylated haemoglobin and fasting serum glucose levels. Potentially Fatal: Severe rhabdomyolysis w/ acute renal failure. Hepatitis, pancreatitis. Rarely, Stevens-Johnson syndrome, anaphylaxis, toxic epidermal necrolysis.

Drug Interactions

May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol. Potentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.

Contraindications

Active liver disease or unexplained persistent elevations of serum transaminases. Concomitant use w/ ciclosporin, gemfibrozil, telaprevir, tipranavir. Pregnancy and lactation.

Mechanism of Action

Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate. This results in the induction of the LDL receptors and stimulation of LDL catabolism, leading to lowered LDL-cholesterol levels. Absorption: Readily absorbed from the GI tract. Bioavailability: Approx 12%. Distribution: Volume of distribution: Approx 381 L. Plasma protein binding: 98%. Metabolism: Metabolised by CYP3A4 isoenzyme to active ortho- and parahydroxylated derivates and an inactive β-oxidation product. Excretion: Via faeces (as metabolites); urine (<2% as unchanged drug). Elimination half-life: Approx 14 hr.

Special Precautions

History of liver disease; patients who consume substantial quantities of alcohol; patients w/ risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to statin therapy initiation. Renal impairment. Childn <10 yr. Premenarcheal females. Monitoring Parameters Monitor creatine kinase (CK) periodically and LFT. Discontinue if there is significant or persistent increase in CK levels, serum aminotransferase levels or evidence of myopathy.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.